Structures multimodal pain management with ERAS protocols and opioid stewardship documentation. Use when managing post-surgical pain, implementing ERAS pathways, or tracking opioid use.
Structures multimodal pain management with ERAS protocols and opioid stewardship documentation.
Postoperative pain is the most common patient concern after surgery, and its management directly affects recovery, length of stay, patient satisfaction (HCAHPS scores), and long-term outcomes. The 2016 CDC Guideline for Prescribing Opioids and subsequent ACS/ERAS Society recommendations have shifted the paradigm from opioid-centric protocols to multimodal analgesia strategies that reduce opioid consumption while maintaining adequate pain control. Institutions that adopt multimodal protocols see 30-40% reductions in opioid use, faster return of bowel function, earlier ambulation, and shorter hospital stays.
Inadequate pain management delays ambulation (increasing VTE and pneumonia risk), impairs pulmonary function (atelectasis, pneumonia), and drives patient dissatisfaction. Conversely, excessive opioid prescribing causes respiratory depression (the leading cause of opioid-related death in hospitalized patients), ileus, urinary retention, and contributes to the opioid epidemic through new persistent use. This skill structures a balanced, evidence-based approach to postoperative pain that prioritizes function and safety.
Perform structured pain assessments at standardized intervals:
Assessment tools:
| Tool | Population | Scale |
|---|---|---|
| Numeric Rating Scale (NRS) | Adults, verbal | 0-10 (0 = none, 10 = worst) |
| Visual Analog Scale (VAS) | Adults, verbal | 0-100 mm line |
| Wong-Baker FACES | Pediatric, non-verbal | 6 faces |
| CPOT (Critical-Care Pain Observation Tool) | Intubated/sedated ICU patients | 0-8 |
| BPS (Behavioral Pain Scale) | Intubated/sedated | 3-12 |
Assessment frequency:
Functional pain goals (document these, not just a NRS number):
Layer non-opioid analgesics as the foundation, adding opioids only for breakthrough pain:
| Medication | Dose | Route | Frequency | Contraindications |
|---|---|---|---|---|
| Acetaminophen | 1000 mg | PO/IV | Q6h scheduled | Liver disease (reduce to 2g/day), hepatic impairment |
| Celecoxib | 200 mg | PO | Q12h (2-3 day course) | Sulfa allergy, CKD (GFR <30), active GI bleed, post-CABG |
| Ketorolac | 15-30 mg | IV | Q6h x 48h max | CKD, GI bleed history, EBL >500 mL, platelet dysfunction |
| Ibuprofen | 400-600 mg | PO | Q6h (transition from ketorolac) | Same as ketorolac |
| Medication | Dose | Route | Frequency | Notes |
|---|---|---|---|---|
| Gabapentin | 300 mg | PO | Q8h | Reduce for renal impairment; caution if age >65, sedation risk |
| Pregabalin | 75 mg | PO | Q12h | Alternative to gabapentin; same precautions |
| Lidocaine IV infusion | 1-2 mg/kg/h | IV | Continuous intraop → 24h postop | Cardiac monitoring required; useful in abdominal surgery |
| Ketamine (sub-anesthetic) | 0.1-0.3 mg/kg/h | IV | Continuous 24-48h | For opioid-tolerant patients; avoid in psychosis, elevated ICP |
| Lidocaine patch 5% | 1-3 patches | Topical | 12h on / 12h off | Low risk; apply adjacent to incision |
| Technique | Indication | Duration | Management |
|---|---|---|---|
| Thoracic epidural | Open thoracic or upper abdominal surgery | 48-72h | Acute Pain Service manages; monitor sensory level, hypotension |
| TAP block (single shot) | Abdominal surgery (laparoscopic or open) | 12-24h | Anesthesia performs; provides somatic wall analgesia |
| TAP block (catheter) | Major abdominal surgery | 48-72h | Continuous local anesthetic infusion |
| Paravertebral block | Thoracic surgery, breast surgery | 12-24h (single shot) | Unilateral; fewer hemodynamic effects than epidural |
| Adductor canal block | Knee surgery | 12-24h | Preserves quadriceps strength (vs. femoral block) |
| Wound infiltration (liposomal bupivacaine) | Various | Up to 72h | Injected at incision closure |
When opioids are required for breakthrough pain (NRS ≥4 despite multimodal regimen):
Inpatient opioid orders:
| Setting | Medication | Dose | Route | Frequency |
|---|---|---|---|---|
| PACU (immediate) | Fentanyl | 25-50 mcg | IV | Q5min PRN (nurse-titrated) |
| Floor — mild/moderate | Oxycodone | 5 mg | PO | Q4h PRN (NRS 4-6) |
| Floor — moderate/severe | Hydromorphone | 0.2-0.4 mg | IV | Q3h PRN (NRS 7-10) |
| PCA (when indicated) | Hydromorphone | 0.2 mg demand, 8 min lockout, 1.2 mg/4h limit | IV | No basal rate |
Opioid stewardship documentation requirements:
Opioid-tolerant patients (defined as ≥60 mg OME/day for ≥1 week):
Opioid-related adverse effect monitoring:
| Parameter | Frequency | Action Threshold |
|---|---|---|
| Respiratory rate | Q1h x 12h after IV opioid, then Q2h | <10 breaths/min → hold opioid, assess, consider naloxone |
| Sedation level (POSS or Ramsay) | With every opioid administration | POSS ≥3 → hold opioid, supplemental O2, escalate |
| Oxygen saturation | Continuous (POD 0-1); spot-check thereafter | SpO2 <92% on RA → assess, supplemental O2 |
| Capnography | Recommended for PCA and high-risk patients | ETCO2 >50 or <30 → assess airway |
| Bowel function | Daily | If no BM by POD 3 → initiate bowel regimen, consider reducing opioids |
| Urinary retention | After Foley removal | >400 mL on bladder scan → straight cath, assess opioid contribution |
Naloxone (Narcan) protocol:
Discharge prescribing framework:
| Procedure Category | Typical Opioid at Discharge | Quantity Limit |
|---|---|---|
| Minor (laparoscopic cholecystectomy, hernia repair) | Oxycodone 5 mg Q6h PRN | 10-15 tablets |
| Moderate (colectomy, hysterectomy) | Oxycodone 5 mg Q4-6h PRN | 15-20 tablets |
| Major (Whipple, open aortic repair) | Oxycodone 5-10 mg Q4-6h PRN | 20-30 tablets |
Mandatory discharge documentation: